NCT05520138View on ClinicalTrials.gov

Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC)

CompletedOBSERVATIONAL
Enrollment

5,506

Participants

Timeline

Start Date

August 29, 2022

Primary Completion Date

June 30, 2023

Study Completion Date

June 30, 2023

Conditions
Prostatic Neoplasms, Castration-Resistant
Interventions
DRUG

Enzalutamide

As provided in real-world setting

DRUG

Abiraterone acetate

As provided in real-world setting

Trial Locations (1)

10017

Pfizer Inc, New York

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05520138 - Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) | Biotech Hunter | Biotech Hunter